<DOC>
	<DOCNO>NCT01240694</DOCNO>
	<brief_summary>The primary objective study evaluate long term safety tolerability repeat administration subcutaneous ( sc ) CEP 33457 injection every 4 week 72 week ( 18 dos ) patient systemic lupus erythematosus ( SLE ) participate previous Cephalon sponsor clinical study CEP 33457 , complete least visit 8 ( week 24 study ) .</brief_summary>
	<brief_title>A Long-Term Study Safety Tolerability Repeated Administration CEP-33457 Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>The patient establish diagnosis systemic lupus erythematosus ( SLE ) define ACR Classification Revised Criteria . The diagnosis fulfil provide least 4 criterion meet . The patient previously participate complete least visit 8 ( week 24 ) Cephalon sponsor clinical study CEP 33457 ( study C33457/2047 ) , investigator 's opinion , would benefit continued participation clinical study . Women must surgically sterile , 2 year postmenopausal , , childbearing potential , use medically accept method contraception , must agree continue use method duration study 30 day discontinuation study drug treatment . The patient New York Heart Association ( NYHA ) Class III IV congestive heart failure . The patient estimate glomerular filtration rate ( eGFR ) less 30 mL/min/1.73 m2 ( via Modification Diet Renal Disease [ MDRD ] equation ) . The patient aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) value great 2 time upper limit normal ( ULN ) total bilirubin level great 1.5 time ULN . The patient plan immunization live live attenuated vaccine within 3 month prior administration first dose study drug 3 month administration last dose study drug . The patient clinically significant abnormality ECG relate SLE , determine investigator . Patients stable ECG change without evidence active cardiovascular disease may participate discretion investigator medical monitor . The patient ongoing active systemic infection require treatment history severe infection , hepatitis pneumonia , 3 month prior administration first dose study drug . Less severe infection 3 month prior administration first dose study drug permit discretion investigator medical monitor . The patient concomitant medical condition unrelated SLE may interfere safety evaluation study drug , determine investigator . The patient history positive test result hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCV Ab ) . The patient know positive history antibody human immunodeficiency virus ( HIV ) HIV disease . The patient history alcohol substance dependence abuse ( exception nicotine ) , accord Diagnostic Statistical Manual Mental Disorders American Psychiatric Association , Fourth Edition , Text Revision ( DSMIVTR ) , within 3 month screen visit study C33457/2047 , current substance abuse . The patient history severe allergic reaction hypersensitivity component study drug . The patient pregnant lactate woman . ( Any woman become pregnant study withdrawn study . ) The patient undergone undergoing treatment another investigational drug treatment lupus within 6 month prior 1st dose study drug receive investigational drug condition within 30 day prior 1st dose study drug , except treatment CEP33457 placebo study C33457/2047 . The patient known history antibody CEP33457 . The patient unlikely comply study protocol unsuitable reason , judge investigator medical monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
</DOC>